Efficacy, Safety and Tolerability of AG013 in Oral Mucositis Compared to Placebo When Administered Three Times Per Day

PHASE2TerminatedINTERVENTIONAL
Enrollment

200

Participants

Timeline

Start Date

July 18, 2017

Primary Completion Date

March 31, 2020

Study Completion Date

July 13, 2020

Conditions
Oral Mucositis
Interventions
BIOLOGICAL

AG013

AG013 is made up of genetically modified (GM) bacteria called Lactococcus lactis (L. lactis). Wild type L. lactis are commonly used to produce dairy products including cheeses and milk. To make AG013, the DNA of L. lactis has been changed in the laboratory to secrete a protein called human Trefoil Factor 1 (hTFF1). hTFF1 is normally secreted in saliva and intestines. Trefoil factors have been shown to be important in protecting and healing mucosal tissues, such as the tissue in the mouth, when these tissues are damaged by cancer therapies such as chemotherapy and radiation therapy.

OTHER

Placebo

Subjects assigned to the placebo group will receive appearance- and taste-matched placebo powder.

Trial Locations (50)

1000

Jules Bordet Institute, Brussels

1090

University Hospital Brussels, Brussels

2650

University Hospital Antwerp, Edegem

2800

St. Maarten General Hospital, Mechelen

3000

University Hospitals Leuven, Leuven

10467

Montefiore Medical Center, Albert Einstein College of Medicine, Department of Radiation Oncology, The Bronx

11042

Northwell Health Cancer Institute / Center for Novel Cancer Therapeutics, Lake Success

14642

University of Rochester Medical Center, Rochester

15232

UPMC Shadyside Hospital, Pittsburgh

19140

Temple University Hospital, Radiation Oncology, Philadelphia

19713

Helen F. Graham Cancer Center, Newark

22903

Radiation Oncology Moser, Charlottesville

24105

University Hospital Schleswig-Holstein, Kiel

28054

Caromont Regional Medical Center, Gastonia

31904

Columbus Regional Research Institute, Columbus

32806

UF Health Cancer Center, Orlando

34125

Hospital Kassel, Kassel

35392

University Hospital Giessen and Marburg, Giessen

40202

Norton Cancer Institute, Multicisciplinary Clinic, Louisville

41063

Clinics Maria Hilf - Hospital St. Franziskus, Mönchengladbach

43210

Ohio State University Comprehensive Cancer Center, Columbus

44708

Mercy Medical Center, Canton

46016

St. Vincent Anderson Regional, Cancer Center, Anderson

47805

Helios Hospital Krefeld, Krefeld

52074

University Hospital Aachen, Aachen

55131

University Hospital Johannes Gutenberg - University of Mainz, Mainz

62526

Decatur Memorial Hospital, Decatur

68167

University Hospital Mannheim, Mannheim

70121

Ochsner Clinic Foundation, New Orleans

71103

Willis-Knighton Cancer Center, Shreveport

77030

University of Texas MD Anderson Cancer Center, Houston

79106

University Hospital Freiburg, Freiburg im Breisgau

81377

Ludwig Maximilians University Hospital, Munich

84112

Huntsman Cancer Hospital, Salt Lake City

85221

Amper Hospital, Dachau

Caritas Klinikum, Saarbrücken

89052

Comprehensive Cancer Centers of Nevada-Henderson, Henderson

89502

Renown Regional Medical Center, Reno

93053

University Hospital Regensburg, Regensburg

98225

PeaceHealth St. Joseph Medical Center, Bellingham

98405

Multicare Health Center, Gig Harbor

99216

Cancer Care NW, Spokane

06030

University of Connecticut Health Center, Farmington

48109-5008

University of Michigan, Ann Arbor

27834-4354

East Carolina Univ School of Dental Medicine, Greenville

PL6 8DH

Derriford Hospital, Plymouth

G12 0YN

Beatson West of Scotland Cancer Center, Glasgow

SE1 9RT

Guy's Hospital, London

M20 4BX

The Christie NHS Foundation Trust, Manchester

TR1 3LJ

Royal Cornwall Hospital, Truro

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Oragenics, Inc.

INDUSTRY

NCT03234465 - Efficacy, Safety and Tolerability of AG013 in Oral Mucositis Compared to Placebo When Administered Three Times Per Day | Biotech Hunter | Biotech Hunter